Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 5, pp 1213–1220 | Cite as

The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials

  • Ye-min Wang
  • Bao-zhe Jin
  • Fang Ai
  • Chang-hong Duan
  • Yi-zhong Lu
  • Ting-fang Dong
  • Qing-lin FuEmail author
Original Article



Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on tumor remission, 1-year survival, and side effects due to radiochemotherapy.


An electronic search was conducted using the databases Pubmed, Medline, EMBASE, Cochrane library, and CNKI, from inception to November 2011. Trials using melatonin as adjunct treatment concurrent with chemotherapy or radiotherapy for cancer were included. Pooled relative risk (RR) for the tumor remission, 1-year survival, and radiochemotherapy-related side effects were calculated using the software Revman 5.0.


The search strategy identified 8 eligible RCTs (n = 761), all of which studied solid tumor cancers. The dosage of melatonin used in the 8 included RCTs was 20 mg orally, once a day. Melatonin significantly improved the complete and partial remission (16.5 vs. 32.6%; RR = 1.95, 95% CI, 1.49–2.54; P < 0.00001) as well as 1-year survival rate (28.4 vs. 52.2%; RR = 1.90; 95% CI, 1.28–2.83; P = 0.001), and dramatically decreased radiochemotherapy-related side effects including thrombocytopenia (19.7 vs. 2.2%; RR = 0.13; 95% CI, 0.06–0.28; P < 0.00001), neurotoxicity (15.2 vs. 2.5%; RR = 0.19; 95% CI, 0.09–0.40; P < 0.0001), and fatigue (49.1 vs. 17.2%; RR = 0.37; 95% CI, 0.28–0.48; P < 0.00001). Effects were consistent across different types of cancer. No severe adverse events were reported.


Melatonin as an adjuvant therapy for cancer led to substantial improvements in tumor remission, 1-year survival, and alleviation of radiochemotherapy-related side effects.


Melatonin Cancer Meta-analysis Remission Survival 


  1. 1.
    Dakshayani KB, Subramanian P, Manivasagam T, Essa MM, Manoharan S (2005) Melatonin modulates the oxidant-antioxidant imbalance during N-nitrosodiethylamine induced hepatocarcinogenesis in rats. J Pharm Pharm Sci 8:316–321PubMedGoogle Scholar
  2. 2.
    Xi SC, Siu SW, Fong SW, Shiu SY (2001) Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 46:52–61PubMedCrossRefGoogle Scholar
  3. 3.
    Vijayalaxmi TCJ, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601PubMedCrossRefGoogle Scholar
  4. 4.
    Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM (2010) Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 12:R107PubMedCrossRefGoogle Scholar
  5. 5.
    Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J (2008) Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 45:532–540PubMedCrossRefGoogle Scholar
  6. 6.
    Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G (1997) Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer 5:126–129PubMedCrossRefGoogle Scholar
  7. 7.
    Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G (1999) Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35:1688–1692PubMedCrossRefGoogle Scholar
  8. 8.
    Kim C, Kim N, Joo H, Youm JB, Park WS, Cuong DV, Park YS, Kim E, Min CK, Han J (2005) Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 46:200–210PubMedCrossRefGoogle Scholar
  9. 9.
    Lissoni P (2002) Is there a role for melatonin in supportive care? Support Care Cancer 10:110–116PubMedCrossRefGoogle Scholar
  10. 10.
    Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G (2003) Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35:12–15PubMedCrossRefGoogle Scholar
  11. 11.
    Yan J, Shen F, Wang K, Wu M (2001) Co-antitumor effect and hepatic protection of melatonin on advanced primary liver cancer treated by transcatheter arterial chemoembolization. Acad J Sec Mil Med Univ 22:858–861Google Scholar
  12. 12.
    Lissoni P, Paolorossi F, Ardizzoia A, Barni S, Chilelli M, Mancuso M, Tancini G, Conti A, Maestroni GJ (1997) A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 23:15–19PubMedCrossRefGoogle Scholar
  13. 13.
    Lissoni P (2007) Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris) 55:198–200CrossRefGoogle Scholar
  14. 14.
    Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, Maestroni G (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53:43–46PubMedCrossRefGoogle Scholar
  15. 15.
    Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P (2003) Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Anticancer Res 23:1951–1954PubMedGoogle Scholar
  16. 16.
    Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E (2011) Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther [Epub ahead of print]Google Scholar
  17. 17.
    Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G, Et A (1992) Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 49:336–339PubMedCrossRefGoogle Scholar
  18. 18.
    Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G (1994) A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 73:699–701PubMedCrossRefGoogle Scholar
  19. 19.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigore L, Parolini D, Colciago M, Rovelli F (2008) Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 28:1377–1381PubMedGoogle Scholar
  20. 20.
    Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, Meregalli S (1996) Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 21:239–242PubMedCrossRefGoogle Scholar
  21. 21.
    Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S, Esposti D, Zubelewicz B, Braczowski R (1995) A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. Oncol Rep 2:871PubMedGoogle Scholar
  22. 22.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R, Et A (1994) A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196–199PubMedCrossRefGoogle Scholar
  23. 23.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ (1990) Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension. Anticancer Res 10:1759–1761PubMedGoogle Scholar
  24. 24.
    Lissoni P, Mandala M, Brivio F (2000) Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin. Eur Urol 38:115–118PubMedCrossRefGoogle Scholar
  25. 25.
    Lissoni P, Pittalis S, Ardizzoia A, Brivio F, Barni S, Tancini G, Pelizzoni F, Maestroni GJ, Zubelewicz B, Braczkowski R (1996) Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Support Care Cancer 4:313–316PubMedCrossRefGoogle Scholar
  26. 26.
    Brackowski R, Zubelewicz B, Romanowski W, Lissoni P, Barni S, Tancini G, Maestroni GJ (1994) Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 8:77–80PubMedGoogle Scholar
  27. 27.
    Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562PubMedCrossRefGoogle Scholar
  28. 28.
    Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR (2008) Melatonin and the immune system in aging. Neuroimmunomodulation 15:272–278PubMedCrossRefGoogle Scholar
  29. 29.
    Schernhammer ES, Razavi P, Li TY, Qureshi AA, Han J (2011) Rotating night shifts and risk of skin cancer in the nurses’ health study. J Natl Cancer Inst 103:602–606PubMedCrossRefGoogle Scholar
  30. 30.
    Adriaens I, Jacquet P, Cortvrindt R, Janssen K, Smitz J (2006) Melatonin has dose-dependent effects on folliculogenesis, oocyte maturation capacity and steroidogenesis. Toxicology 228:333–343PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ye-min Wang
    • 1
  • Bao-zhe Jin
    • 2
  • Fang Ai
    • 2
  • Chang-hong Duan
    • 2
  • Yi-zhong Lu
    • 1
  • Ting-fang Dong
    • 1
  • Qing-lin Fu
    • 2
    Email author
  1. 1.Department of PharmacyThe First Affiliated Hospital of Xinxiang Medical UniversityXinxiangChina
  2. 2.Department of SurgeryThe First Affiliated Hospital of Xinxiang Medical UniversityXinxiangChina

Personalised recommendations